Br J Cancer: Systemic inflammation scores are associated with survival prognosis in patients with brain metastasis tumors

Brain metastatic tumor (BMs) as a common solid cancer, is a life-threatening complication.
immunosuppressor therapy has now shown activity on BM.
, asymptomatic BM patients were more clinically effective than patients with neurological symptoms who needed steroid treatment.
systemic inflammatory scores, including the ratio of neutral granulocytes to lymphocytes (NLR), white blood cells to lymphocytes (LLR), plate plate and lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and C-reactive protein/albumin ratio (CRP/Alb) have been shown to affect tumor control and ultimately the survival prognosis of patients with extracranial metastatic cancer.
addition, recently identified systemic inflammatory markers, including pre-treatment CRP, NLR, and MLR, were associated with progression-free survival (PFS) and overall survival (OS) in patients treated with immuno-checkpoint inhibitors.
systemic inflammation scores were associated with the condition of extracranial diseases, however, no studies have been conducted to reveal the prognostic effects of systemic inflammation scores in the BM patients' queue.
, the study was designed to analyze the correlation between systemic inflammatory scores such as NLR, LLR, PLR, MLR, and CRP/Alb and the prognostication of survival in BM patients.
researchers, who had a systemic inflammation score associated with the overall survival rate of patients, collected 1,250 newly diagnosed patients with brain metastasis tumors from the Vienna Brain Transfer Registry.
studies showed that patients with intracranial metastatic cancer had higher PLR and CRP/Alb scores, while 20 points were lower for noncranial metastasis.
NLR, LLR, PLR, MLR, and CRP/Alb correspond to a patient's longer total lifetime (OS).
in multivariable analyses with hierarchical prognossis, NLR, LLR, PLR, MLR, and CRP/Alb remain independent OS-related factors in BM diagnostics.
, the results showed that systemic inflammatory scores such as NLR, LLR, PLR, MLR, and CRP/Alb were associated with OS in BM patients.
researchers have also raised the need for further exploration of relevant immunomodulation therapies.